Efficacy of PEG-IFN alfa-2b plus ribabirin and HMG-CoA reductase inhibitor combination antiviral therapy ; pilot study
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 14 May 2007
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; HMG-CoA reductase inhibitors; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 14 May 2007 New trial record.